Literature DB >> 18442221

Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring.

Sebastian Radestock1, Tanja Weil, Steffen Renner.   

Abstract

The current study investigates the combination of two recently reported techniques for the improvement of homology model-based virtual screening for G-protein coupled receptor (GPCR) ligands. First, ligand-supported homology modeling was used to generate receptor models that were in agreement with mutagenesis data and structure-activity relationship information of the ligands. Second, interaction patterns from known ligands to the receptor were applied for scoring and rank ordering compounds from a virtual library using ligand-receptor interaction fingerprint-based similarity (IFS). Our approach was evaluated in retrospective virtual screening experiments for antagonists of the metabotropic glutamate receptor (mGluR) subtype 5. The results of our approach were compared to the results obtained by conventional scoring functions (Dock-Score, PMF-Score, Gold-Score, ChemScore, and FlexX-Score). The IFS lead to significantly higher enrichment rates, relative to the competing scoring functions. Though using a target-biased scoring approach, the results were not biased toward the chemical classes of the reference structures. Our results indicate that the presented approach has the potential to serve as a general setup for successful structure-based GPCR virtual screening.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442221     DOI: 10.1021/ci8000265

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  23 in total

1.  FFA1-selective agonistic activity based on docking simulation using FFA1 and GPR120 homology models.

Authors:  Masato Takeuchi; Akira Hirasawa; Takafumi Hara; Ikuo Kimura; Tatsuya Hirano; Takayoshi Suzuki; Naoki Miyata; Takeo Awaji; Masaji Ishiguro; Gozoh Tsujimoto
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

2.  3D structural models of transmembrane proteins.

Authors:  Alexandre G de Brevern
Journal:  Methods Mol Biol       Date:  2010

Review 3.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Closing the side-chain gap in protein loop modeling.

Authors:  Karen A Rossi; Akbar Nayeem; Carolyn A Weigelt; Stanley R Krystek
Journal:  J Comput Aided Mol Des       Date:  2009-05-21       Impact factor: 3.686

Review 5.  Recent advances in structure-based virtual screening of G-protein coupled receptors.

Authors:  Subramaniam Ananthan; Wei Zhang; Judith Varady Hobrath
Journal:  AAPS J       Date:  2009-03-17       Impact factor: 4.009

6.  Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the beta2-adrenergic receptor and the human adenosine A2A receptor.

Authors:  Farag F Sherbiny; Anke C Schiedel; Astrid Maass; Christa E Müller
Journal:  J Comput Aided Mol Des       Date:  2009-11       Impact factor: 3.686

Review 7.  The impact of GPCR structures on pharmacology and structure-based drug design.

Authors:  Miles Congreve; Fiona Marshall
Journal:  Br J Pharmacol       Date:  2009-11-13       Impact factor: 8.739

Review 8.  In silico studies on DARC.

Authors:  Alexandre G de Brevern; Ludovic Autin; Yves Colin; Olivier Bertrand; Catherine Etchebest
Journal:  Infect Disord Drug Targets       Date:  2009-06

9.  New opportunities to fight against infectious diseases and to identify pertinent drug targets with novel methodologies.

Authors:  Alexandre G de Brevern
Journal:  Infect Disord Drug Targets       Date:  2009-06

Review 10.  Biophysical characterization of G-protein coupled receptor-peptide ligand binding.

Authors:  David N Langelaan; Pascaline Ngweniform; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2011-04       Impact factor: 3.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.